{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Collection of Pregnancy Information', 'Male subjects with partners who become pregnant', \"The Investigator will attempt to collect pregnancy information on any male subject's female\", 'partner who becomes pregnant while the male subject is in this study. This applies only to', 'male subjects who receive study treatment.', 'After obtaining the necessary signed informed consent from the pregnant female partner', 'directly, the Investigator will record pregnancy information on the appropriate pregnancy', \"form and submit it to the Sponsor within 24 hours of learning of the partner's pregnancy. The\", 'female partner will also be followed to determine the outcome of the pregnancy. Information', 'on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow-', 'up will be no longer than 6 to 8 weeks following the estimated delivery date. Any', 'termination of the pregnancy will be reported regardless of fetal status (presence or absence', 'of anomalies) or indication for the procedure.', 'Female subjects who become pregnant', 'The Investigator will collect pregnancy information on any female subject who becomes', 'pregnant while participating in this study. Information will be recorded on the appropriate', \"form and submitted to the Sponsor within 24 hours of learning of a subject's pregnancy.\", 'The subject will be followed to determine the outcome of the pregnancy. The Investigator', 'will collect follow-up information on the subject and the neonate and the information will be', 'forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 8', 'weeks after the delivery date. Any termination of pregnancy will be reported, regardless of', 'fetal status (presence or absence of anomalies) or indication for the procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or', 'elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous', 'abortion is always considered to be an SAE and will be reported as such.', 'Any post-study pregnancy related SAE considered reasonably related to the study treatment', 'by the Investigator will be reported to the Sponsor as described in Section 8.3.5. While the', 'Investigator is not obligated to actively seek this information in former subjects, he or she', 'may learn of an SAE through spontaneous reporting.', 'Any female subject who becomes pregnant while participating in the study will be withdrawn', 'from the study.', '29 October 2019', '77']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Appendix 7', 'Genetics', 'Use/Analysis of DNA/mRNA', \"Genetic variation may impact a subject's response to study treatment, susceptibility to, and\", 'severity and progression of disease. Variable response to study treatment may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and excretion;', 'mechanism of action of the drug; disease etiology; and/or molecular subtype of the disease', 'being treated. Therefore, where local regulations and IRB/IEC allow, a blood sample will be', 'collected for DNA analysis from consenting subjects.', 'DNA/mRNA samples will be used to study disease pathogenesis and to determine potential', 'genetic biomarkers of response to treatment. Genetic research may consist of the analysis of', '1 or more candidate genes or the analysis of genetic markers throughout the genome or', 'analysis of the entire genome.', 'DNA samples will be analyzed for genetic analysis.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors involved', 'in the response to study treatment or study treatments of this class to understand study', 'disease or related conditions.', 'Samples will be sent to the designated laboratory where they will be stored according to ICH', 'GCP and GLP requirements with adequate measures to protect confidentiality. Genetic', 'analysis using DNA/mRNA samples may be performed by additional third party (eg, a', 'university Investigator) designated by the Sponsor. The results of genetic analyses may be', 'reported in the CSR or in a separate study summary.', 'The samples may be retained while research on study treatment or study treatments of this', 'class or indication continues as described in the ICF.', '29 October 2019', '78']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Appendix 8', 'Clinical Global Impression', 'Change in modified', 'JDA severity index total', 'Category', 'score for GPP', 'and/or', 'Category description', 'Very much improved', 'Reduction by 3 or >points', 'or', 'Clear or almost clear of signs of GPP', 'Much improved', 'Reduction by 1 or 2', 'or', 'At least one of the following:', 'points', 'Area of erythema with pustules (%)', 'reduced by <30%', 'or', 'Clinically meaningful improvement', 'in at least 2 other components of', 'the modified JDA severity index', 'for GPP (area of erythema, area of', 'edema, fever, WBC, CRP, Alb)', 'Minimally improved', '0 points (no change)', 'and', 'At least one of the following:', 'Area of erythema with pustules (%)', 'reduced by 20%', 'or', 'Clinically meaningful improvement', 'in at least 1 other components of', 'the modified JDA severity index', 'for GPP (area of erythema, area of', 'edema, fever, white blood cell', '[WBC], C-reactive protein [CRP],', 'Alb)', 'No change', '0 points (no change)', 'and', 'Not meeting the other criteria of \"minimally', 'improved\"', 'Worsened', '>+ 1 point', 'Not applicable', '29 October 2019', '79']\n\n###\n\n", "completion": "END"}